

# CANCER RESEARCH FOUNDA T I O N

The Mission of The Cancer Research Foundation Is To Help Find The Cures For Cancer Through Funding Laboratory and Clinical Research.

## Connections

WITH FRIENDS

Guest Columnist: Nicholas J. Vogelzang, M.D., Fred C. Buffett Professor of Medicine and Director, University of Chicago Cancer Research Center

The problem of cancer continues to pervade the consciousness of the people of the United States. The intense public concern about cancer can be attributed in part to the decline in death rates due to stroke and heart attacks in the aging population. At the same time, diseases like Alzheimer's, diabetes, and other degenerative diseases such as cancer continue to threaten the growing elderly population of the United States. Because cancer strikes the greatest fear within most Americans, the public has encouraged and generously supported cancer research since 1971 when the "war on cancer" was officially declared. Yet the Cancer Research Foundation (CRF) founded by Maurice Goldblatt has been fighting the "war on cancer" since 1944 when Maurice's brother Nathan died of the disease. Over the ensuing years the CRF has supported University of Chicago cancer researchers with over fourteen million dollars in funding.

In light of this official 30-year war on cancer (and the CRF's more than 50-year war), the most pressing question for those who have supported cancer research is: How have we, the medical community, made use of your funds and how will we use your funds during the next 30 to 50 years? Such questions are extremely important, would require volumes to answer, and probably could never be answered fully.

Yet one statistic summarizes the answer: we can confidently report that cancer-related deaths have dropped below the 50% mark for the first time. That is, over 50% of all cancer patients are cured of their disease! In contrast, the



cancer cure rate in the 1940s was barely 20%! These cures are the result of innovative surgical and radiation techniques, and increasingly sophisticated chemotherapy and immunotherapeutic approaches. Improved diagnostic and molecular markers that predict prognosis have also contributed to the high cure rate. In fact, of the

150+ cancers known to man, virtually all can be cured if detected at an early enough stage. Additionally, with the continual support of countless individuals, scientists, and clinicians, the medical community has seen significant advances in therapies for cancers that are rarely detected at an early stage, such as mesothelioma. I tell my patients that we have cured about 50% of all cancers and I look forward to seeing the remaining 50% cured before I retire!

How will we accomplish this lofty goal? The big answer lies in the recent completion of the entire "blueprint of life", the human genome. The wealth of information provided by this exciting scientific accomplishment will enable researchers to determine the precise genetic sequence of each human cancer. Because individual cancers will differ in their specific genetic alterations, the technique of genetically "fingerprinting" or "blueprinting" cancer will become a vital tool in the development of new anticancer therapies. Fingerprinting or "blueprinting" tumors will allow

investigators to identify which genes are turned "on" or "off" beyond normal levels. Results of these analyses will identify possible targets for new

*"If I have seen further ... it is by standing upon the shoulders of giants."*

Isaac Newton, 1675

*...continued on page 9*

# Medical Ethics: A Transcribed Conversation

First broadcast on WBEZ Radio, FM 91.5, and printed with permission.

Parts I, II, and III were published in our newsletters of April and October, 1999, and Spring, 2000

For copies, please call our office.

## Identification of Participants:

**VL:** Victoria Lautman, WBEZ

**MS:** Dr. Mark Siegler, Professor in the department of Medicine at the University of Chicago, where he is also the founding director of the MacLean Center for Clinical Medical Ethics

**AG:** Ann Dudley Goldblatt, assistant director for the MacLean Center for Clinical Medical Ethics, who also teaches in the law school, the medical school and the college at the University of Chicago

**VL:** Let's hear from Tim.

**Tim:** I'm a naprapath. I deal with a lot of patients seeking alternative medical care. A few years ago there was a case with a young boy named Chad Green, and one of the ethical issues was the patient's right to choose alternative treatments. I wondered how you deal with that.

**AG:** It wasn't the patient, it was the patient's parents in that case. He was 2 1/2. But - and it was a laetrile - they wanted to use laetrile for leukemia. The patient's right to choose medicine, a competent adult, full right, absolutely, unless there's a contagious disease involved. Parents choosing alternative therapies for children can

approach child neglect, medical neglect. I think recently we've become more willing to permit

alternative therapies, particularly when it's not a life-endangering situation, or when the prognosis with any kind of treatment is grim. So there have been other cases that have permitted naturopathic or laetrile treatment, but it's a very difficult problem with small children.

**VL:** Those must be, particularly the issues with small children, some of the most difficult work that you have to do, and is there a proportion of the pediatric, neonatal, or just the childhood, part of your job? Is that more time-consuming than the other parts, do you get the same number of patients, do you spend more time on certain types of patients?

**MS:** I would think that in our group it's probably 50-50, adult to pediatric. But our group does have 4 trained pediatricians, some neonatologists, some in the older infant or child intensive care unit, and some general pediatricians who are trained in ethics and pediatrics. They're a wonderful resource. Dr. Lantos is the associate director of the program, and Dr. Meadow, Dr. Sing, and Dr. Ross are all core participants in our group, in part because of the reason you raised: the frequency with which these complicated pediatric problems come up. Tim's question and Mrs. Goldblatt's answer highlight the fact: how different the ethical standards might be for competent adults compared to infants and children.

**AG:** We also have problems with pregnant women, fetal, as opposed to the patient. Who's the patient? So the edges of life I think get a majority of our cases. Very new babies and dying individuals.

**VL:** Because there is so much more

premature birth, and viability is being pushed to this extreme level that never existed before, your job is just

going to get more complicated all the time. We have a lot more questions. Sarah: I have a question about what happens if you have an elderly patient who wants to sign a denial of treatment form because that patient feels like a burden to the family. What do you do when there are some members of the family who want the person to sign that and some members that don't, and when it has to do with something like CPR, something that's not very intrusive, but if you sign that piece of paper it won't happen, is there anything to do with the Hippocratic oath, is there any kind of procedure that a doctor has to come and talk to the patient about, or is there any way of determining if the patient is in a mental place where he can make that decision for himself?

**AG:** OK. Absolutely. A patient must have the capacity to make that decision and I would say it is essential for a physician or other knowledgeable health care worker to discuss CPR with the patient. If the patient doesn't have the capacity to decide competently, then anything he or she signs will not be effective. The problem of not being a burden just brings up the issue that it's unconscionable that we don't have some kind of health care for everyone in this country, the fact that we have



*Dr. Mark Siegler*



*Ann Dudley Goldblatt*

# Medical Ethics: A Transcribed Conversation

(Continued from Page 2)

to beggar our families in order to get decent end of life care in some situations is unacceptable, but true.

**MS:** I agree with what you've said.

**VL:** Another question: Judy - a question about gene therapy.

**Judy:** I've become concerned about some aspects of gene therapy, specifically the possibility of in-the-future pharmaceutical companies patenting genetic material or techniques. And I know this isn't really related to clinical situations right now but I could imagine that happening in the future, and I'd like the opinions of your guests.

**VL:** That's interesting. It makes we wonder about if they ever wonder about cloning a body or a part of a body, are you going to have a different standard for the clone than you would for - ?

**MS:** The cloning of the human and the question of genetic therapy are both in the future. Neither one has yet happened, you know. There has not been yet an effective gene therapy developed. I think Judy's concerns about the likelihood that pharmaceutical companies may want to patent an effect generic therapy is a real concern. Just the way pharmaceutical companies in our country have been encouraged to patent effective new medicines even when they're breakthroughs. I'm not so sure that the patenting of genetic techniques, approaches to studying genes and gene therapy, are likely to be permitted. We're dealing with a new field that's just evolving, and I think it's going to take a huge amount of thoughtfulness legally, socially, politically to resolve the kind of issues you raise.

**VL:** I think that people still have questions about special treatment of people receiving organs and how an

ethicist might affect that.

**Judy:** I'd like their comments about the Mickey Mantle case and how that came about.

**VL:** Uh oh. Whatever you just said, it had a huge impact on these two.

They're pointing, they're wondering who's going to answer this one.

Explain this. I'm not sure what this case is.

**AG:** Mickey Mantle needed a liver, and got one, although he probably was an inappropriate recipient in some ways.

**MS:** I got into a lot of problems over the Mickey Mantle case when I was quoted in one of the newspapers saying that, in general, people should wait their turns on the list according to their medical need and length of time, but that Mickey Mantle - here I'm quoting myself from some years ago- was a true American hero who should go to the top of the list.

I'm sorry that I said that. I don't believe it anymore. And people thought that, in fact, Mickey Mantle was pushed to the top of the list because he got a liver in a few days, whereas other people wait months or even a year to get a liver. It turns out

that one of the doctors I spoke with last week, who was in Dallas at the time, says that in fact the liver that Mr. Mantle got was one that had been turned down by many other programs around the country. And so, that in fact, he had not gotten pushed to the head of the list.

**AG:** Basically, ethically, you should transplant on the basis of objective medical criteria and not celebrity status.

**MS:** I agree.

**VL:** This has just been so interesting. There are still a lot of people waiting. I'm so sorry that we have not gotten to all the questions. We'll just have to revisit this topic again. I really want to thank Dr. Mark Siegler, who is professor in the department of medicine and a founding director of the McLean Center for Clinical Medical Ethics at the University of Chicago. Ann Dudley Goldblatt, also there, is the assistant director, and is a teacher in the law school, the medical school, and the college at the University of Chicago. Thank you both so much for joining me today.

**MS:** Thank you for having us.

**VL:** WBEZ Chicago

## CARSON PIRIE SCOTT COMMUNITY DAY

Saturday, November 18, 2000

*Carson Pirie Scott has invited the Cancer Research Foundation, along with public and private schools and other non-profit organizations, to participate in a day of fun and savings.*

*If you will send us \$5.00, along with your name and address in the enclosed envelope, we will mail you a ticket packet. On November 18, you can use the coupons in your ticket packet to save money on purchases and to enter a drawing for a vacation.*

*We will use your \$5.00 contribution to fund cancer research projects in Chicago.*



## Edwin L. Ferguson, Jr., Ph.D.

Associate Professor  
Department of Molecular Genetics and  
Cellular Biology  
University of Chicago

*Cancer Research Foundation Fletcher Scholar 1999  
Dr. Ferguson's research focuses on stem cells and  
their use in cancer therapy.*

**W**e are not accustomed to thinking that the human body has the potential for massive tissue regeneration and repair. However, in every individual, many differentiated cell types, such as red blood cells or skin cells, have a short lifetime and must be replaced at regular intervals. Normally when a cell differentiates it stops dividing, becomes specialized to perform a particular function, and ultimately dies. How then can differentiated cells be continually renewed? The answer lies in the action of a remarkable class of cells, called stem cells. A stem cell is a non-differentiated cell that has a unique property. When a stem cell divides it produces two types of cells: a cell like itself, and a cell that differentiates. The capacity of various types of stem cells for self renewal thus assures the continual replacement of many differentiated tissues throughout our lives.

The isolation, culture, and characterization of different types of stem cells could be the first step toward the ultimate goal of tissue restoration through stem cell transplantation. Such therapy could be vital to combat diseases that cause tissue degeneration, ranging from

cardiovascular disease to Alzheimer's and Parkinson's diseases, to certain types of diabetes. The use of stem cells in cancer treatment could also be widespread. Certain cancers respond to chemotherapy. However, while the underlying purpose of chemotherapy is to kill the rapidly dividing cancer cells, it has the unavoidable side effect of killing all rapidly dividing normal cells in the body, including the cells of the hematopoietic (circulatory) system. It therefore becomes necessary to repopulate the cells of the circulatory system after successful chemotherapy. The ideal solution would be isolation of the patient's own hematopoietic stem cells before the onset of therapy, the culture of these cells during therapy, and their reimplantation after the completion of therapy.

However, much basic knowledge about stem cells must be gained before they can be used to combat disease. First and foremost, we must understand at a molecular level why one daughter of a stem cell remains as a stem cell while the other daughter differentiates. In work very generously supported by the Fletcher Scholar Award from the Cancer Research Foundation, my lab is

attempting to address this question for a particular type of stem cell, one that is present in the fruit fly *Drosophila melanogaster*. While the fruit fly may seem far removed from humans, work over the past fifteen years has demonstrated multiple times that similar molecular mechanisms are used to control cell behavior and function in both fruit flies and mammals. Moreover, the fruit fly is an unparalleled system in which to perform genetic experiments.

We have initiated a series of experiments that should allow us to perturb the pattern of division of this particular stem cell. While stem cells normally divide to produce two distinct cell types, we will use the tools of genetics to cause this particular type of stem cell to divide to produce two cells of the same type, either two stem cells or two differentiated progeny, depending on the experimental conditions we use. By manipulating the patterns of cell division in one particular type of stem cell, we expect to obtain insights into the molecular programs responsible for the maintenance and differentiation of stem cells in all organisms, thus furthering their ultimate use to alleviate disease in humans.

Accountants and  
Management Consultants  
Grant Thornton LLP  
The US Member Firm of  
Grant Thornton International

## Report of Independent Certified Public Accountants

**Board of Trustees  
The Cancer Research Foundation**

We have audited the accompanying statement of financial position of The Cancer Research Foundation as of March 31, 2000 and 1999, and the related statements of activities and changes in net assets and cash flows for the years then ended. These financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Cancer Research Foundation as of March 31, 2000 and 1999, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Chicago, Illinois  
May 26, 2000



700 One Prudential Plaza  
130 E Randolph Drive  
Chicago, IL 60601-6203  
Tel: 312-856-0200

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

ASSETS

	2000	1999
Cash and cash equivalents.....	\$ 33,837	\$ 99,061
Accrued interest receivable.....	23,303	20,759
Prepaid assets .....	6,687	6,499
Accounts receivable.....	732,621	683,005
Investments.....	4,825,758	4,700,839
Equipment, net .....	2,792	3,659
TOTAL ASSETS.....	\$5,624,998	\$ 5,513,822

LIABILITIES AND NET ASSETS

The Cancer Research Foundation  
STATEMENTS OF  
FINANCIAL POSITION  
March 31, 2000 and 1999

<b>Liabilities</b>		
Unconditional grants payable .....	\$ 150,048	\$ 174,638
Accrued expenses .....	12,019	1,113
Total liabilities.....	162,067	175,751
<b>Net assets</b>		
Unrestricted .....	4,020,045	3,944,801
Temporarily restricted .....	732,621	683,005
Permanently restricted.....	710,265	710,265
Total net assets .....	5,462,931	5,338,071
TOTAL LIABILITIES AND NET ASSETS.....	5,624,998	\$5,513,822

# CANCERRESEARCH

F O U N D A T I O N

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

The Cancer Research Foundation  
**STATEMENTS OF  
ACTIVITIES AND CHANGES  
IN NET ASSETS**  
Year ended March 31, 2000

	Unrestricted	Temporarily restricted	Permanently restricted	Total
<b>Operating revenue</b>				
Public support contributions .....	\$ 169,541	\$ -	\$ -	\$ 169,541
Investment income .....	118,086	-	-	118,086
Change in value of split interest agreements .....	-	49,616	-	49,616
<b>Total operating revenue .....</b>	<b>287,627</b>	<b>49,616</b>	<b>-</b>	<b>337,243</b>
<b>Operating expenses</b>				
<b>Program services</b>				
<b>Contributions and grants to</b>				
UCCRF Dr. Hochstrasser .....	-	-	-	-
UCCRF Dr. Iyer .....	-	-	-	-
UCCRF Dr. Staley .....	50,048	-	-	50,048
UCCRF Dr. Lahn .....	50,000	-	-	50,000
UCCRF Dr. Conzen .....	50,000	-	-	50,000
UCCRF Dr. Hoff .....	50,000	-	-	50,000
UCCRF Dr. Shilyansky .....	50,000	-	-	50,000
UCCRF Dr. Thirman .....	-	-	-	-
UCCRF Dr. Franzoso .....	-	-	-	-
UCCRF Dr. Du .....	-	-	-	-
UCCRF Dr. Correll .....	-	-	-	-
Northwestern University .....	5,000	-	-	5,000
Miscellaneous gifts .....	5,100	-	-	5,100
General expenses .....	54,647	-	-	54,647
<b>Total program services .....</b>	<b>314,795</b>	<b>-</b>	<b>-</b>	<b>314,795</b>
<b>Supporting services</b>				
Management and general .....	36,148	-	-	36,148
Fund raising .....	50,299	-	-	50,299
<b>Total supporting services .....</b>	<b>86,447</b>	<b>-</b>	<b>-</b>	<b>86,447</b>
<b>Total operating expenses .....</b>	<b>401,242</b>	<b>-</b>	<b>-</b>	<b>401,242</b>
<b>Net operating (expenses) revenues .....</b>	<b>(113,615)</b>	<b>49,616</b>	<b>-</b>	<b>(63,999)</b>
Realized gain on investments .....	315,622	-	-	315,622
Unrealized losses on investments .....	(126,763)	-	-	(126,763)
<b>Total other gains (losses) .....</b>	<b>188,859</b>	<b>-</b>	<b>-</b>	<b>188,859</b>
<b>Change in net assets .....</b>	<b>75,244</b>	<b>49,616</b>	<b>-</b>	<b>124,860</b>
Net assets, beginning of year .....	3,944,801	683,005	710,265	5,338,071
<b>Net assets, end of year .....</b>	<b>\$ 4,020,045</b>	<b>\$ 732,621</b>	<b>\$ 710,265</b>	<b>\$ 5,462,931</b>

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

The Cancer Research Foundation  
**STATEMENTS OF  
FUNCTIONAL EXPENSES**  
Year ended March 31, 2000

	Program services	Management and general	Fund raising	Total
<b>Contributions and grants .....</b>	<b>\$ 260,148</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 260,148</b>
Advertising .....	-	-	25,210	25,210
Depreciation .....	434	433	-	867
Dues and subscriptions .....	964	964	963	2,891
Employee benefits .....	5,816	4,653	1,163	11,632
Internet .....	2,013	-	2,012	4,025
Legal and professional .....	3,378	3,378	1,689	8,445
Liability/worker's compensation .....	-	815	-	815
Meeting expense .....	572	571	571	1,714
Miscellaneous .....	90	90	90	270
Newsletter .....	8,758	-	8,757	17,515
Payroll and taxes .....	22,319	17,856	4,464	44,639
Postage and office supplies .....	1,765	1,765	1,765	5,295
Rent .....	5,388	4,310	1,077	10,775
Special Events .....	1,928	-	1,928	3,856
Stationery and printing .....	-	91	-	91
Telephone .....	1,222	1,222	610	3,054
<b>Total .....</b>	<b>\$ 314,795</b>	<b>\$ 36,148</b>	<b>\$ 50,299</b>	<b>\$ 401,242</b>

**CANCERRESEARCH**  
F O U N D A T I O N

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

The Cancer Research Foundation  
STATEMENTS OF  
ACTIVITIES AND CHANGES  
IN NET ASSETS – CONTINUED  
Year ended March 31, 1999

	Unrestricted	Temporarily restricted	Permanently restricted	Total
<b>Operating revenue</b>				
Public support contributions .....	\$ 364,489	\$ 76,345	\$ -	\$ 440,824
Investment income .....	105,910	-	-	105,910
Change in value of split interest agreements	-	26,143	-	26,143
<b>Total operating revenue .....</b>	<b>470,399</b>	<b>102,488</b>	<b>-</b>	<b>572,887</b>
<b>Operating expenses</b>				
<b>Program services</b>				
Contributions and grants to				
UCCRF Dr. Hochstrasser .....	100,000	-	-	100,000
UCCRF Dr. Iyer .....	50,479	-	-	50,479
UCCRF Dr. Thirman .....	50,000	-	-	50,000
UCCRF Dr. Franzoso .....	50,000	-	-	50,000
UCCRF Dr. Du .....	50,000	-	-	50,000
UCCRF Dr. Correll .....	49,538	-	-	49,438
Northwestern University .....	5,000	-	-	5,000
Miscellaneous gifts .....	3,700	-	-	3,700
General expenses .....	51,391	-	-	51,391
<b>Total program services .....</b>	<b>410,108</b>	<b>-</b>	<b>-</b>	<b>410,108</b>
<b>Supporting services</b>				
Management and general .....	41,313	-	-	41,313
Fund raising .....	43,981	-	-	43,981
<b>Total supporting services .....</b>	<b>85,294</b>	<b>-</b>	<b>-</b>	<b>85,294</b>
<b>Total operating expenses .....</b>	<b>495,402</b>	<b>-</b>	<b>-</b>	<b>495,402</b>
Net operating (expenses) revenues .....	(25,003)	102,488	-	77,485
Realized gain on investments .....	443,179	-	-	443,179
Unrealized losses on investments .....	(653,289)	-	-	(653,289)
<b>Total other losses .....</b>	<b>(210,110)</b>	<b>-</b>	<b>-</b>	<b>(210,110)</b>
<b>Change in net assets.....</b>	<b>(235,113)</b>	<b>102,488</b>	<b>-</b>	<b>(132,625)</b>
Net assets, beginning of year, as restated (note C) .....	4,179,914	580,517	710,265	5,470,696
<b>Net assets, end of year.....</b>	<b>\$ 3,944,801</b>	<b>\$ 683,005</b>	<b>\$ 710,265</b>	<b>\$ 5,338,071</b>

The accompanying notes are an integral part of these statements.

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

The Cancer Research Foundation  
STATEMENTS OF  
FUNCTIONAL EXPENSES –  
CONTINUED  
Year ended March 31, 1999

	Program services	Management and general	Fund raising	Total
Contributions and grants .....	\$ 358,717	\$ -	\$ -	\$ 358,717
Payroll and taxes .....	21,512	17,210	4,302	43,024
Legal and professional .....	4,504	4,504	2,253	11,261
Telephone.....	844	843	422	2,109
Postage and office supplies.....	1,030	1,030	1,029	3,089
Advertising .....	-	-	21,224	21,224
Rent .....	4,497	3,597	899	8,993
Meeting expense .....	268	268	267	803
Stationery and printing .....	-	6,542	-	6,542
Liability/worker's compensation.....	-	875	-	875
Newsletter .....	9,008	-	9,008	18,016
Internet .....	2,051	-	2,051	4,102
Employee benefits.....	6,154	4,923	1,230	12,307
Dues and subscriptions.....	1,097	1,096	1,096	3,289
Depreciation .....	225	225	-	450
Miscellaneous .....	201	200	200	601
<b>Total .....</b>	<b>\$ 410,108</b>	<b>\$ 41,313</b>	<b>\$ 43,981</b>	<b>\$495,402</b>

The accompanying notes are an integral part of these statements.

# CANCERRESEARCH F O U N D A T I O N

FINANCIAL STATEMENTS AND REPORT OF  
INDEPENDENT CERTIFIED PUBLIC  
ACCOUNTANTS  
THE CANCER RESEARCH FOUNDATION  
MARCH 31, 2000 AND 1999

	2000	1999
<b>Cash flows from operating activities</b>		
Change in net assets .....	\$ 124,860	\$ (132,625)
Adjustments to reconcile change in net assets to net cash used in operating activities		
Net realized and unrealized (gain) loss on investments.....	(188,859)	210,110
Depreciation expense.....	867	450
Increase in accounts receivable.....	(49,616)	(102,488)
(Increase) decrease in accrued interest receivable.....	(2,544)	8,767
(Increase) decrease in prepaid assets.....	(188)	493
Increase in accrued expenses .....	10,906	160
Decrease in grants payable.....	(24,590)	(350,362)
<b>Total cash used in operating activities.....</b>	<b>(129,164)</b>	<b>(365,495)</b>
<b>Cash flows from investing activities</b>		
Purchase of equipment.....	-	(2,080)
Proceeds from sale of investments .....	2,619,586	1,741,403
Purchases of investments.....	(2,555,646)	(1,306,083)
<b>Total cash provided by investing activities.....</b>	<b>63,940</b>	<b>433,240</b>
(Decrease) increase in cash and cash equivalents.....	(65,224)	67,745
Cash and cash equivalents, beginning of year.....	99,061	31,316
Cash and cash equivalents, end of year.....	<u>\$ 33,837</u>	<u>\$ 99,061</u>

The Cancer Research Foundation  
**STATEMENTS OF CASH FLOWS**  
Year ended March 31, 2000 and 1999

The accompanying notes are an integral part of these statements.

## The Cancer Research Foundation NOTES TO FINANCIAL STATEMENTS March 31, 2000 and 1999

**NOTE A - NATURE OF PROGRAM SERVICES**

The purpose of The Cancer Research Foundation (the "Foundation") is to obtain and distribute funds to recognized doctors, hospitals, laboratories, institutes, and centers engaged in cancer research.

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation** - The financial statements of the Foundation have been prepared on the accrual basis.

**Classification of Net Assets** - The Foundation's net assets have been grouped into the following two classes:

Unrestricted - Net assets that are not subject to donor-imposed stipulations. Unrestricted net assets may be designated for specific purposes by action of the Board of Trustees or may otherwise be limited by contractual agreements with outside parties.

Permanently Restricted - Net assets subject to donor-imposed stipulations that they be maintained permanently by the Foundation. Generally, the donors of these assets permit the Foundation to use all or part of the income earned on these assets. Permanently restricted assets consist of the Foundation's endowment fund.

**Grants** - Grants are recorded as expenses when the Board approves the grants. Grants approved by the Board, but not yet paid, are recorded as liabilities in the balance sheet.

**Cash Equivalents** - The Foundation considers all liquid investments purchased with an original maturity of three months or less and designated to be used to support daily operations to be cash equivalents.

**Investments** - Investments are carried at fair market value, based on quoted market prices. Interest and dividends are included in operating revenues as investment income. Realized and unrealized gains and losses are separately stated as other gains and losses on the statement of activities.

**Equipment** - Equipment purchased by the Foundation is stated at cost. Depreciation of assets begins when the assets are placed in service. Depreciation is computed using the straight-line method over the estimated useful life of equipment of five years.

**Use of Estimates** - The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may vary from those estimates.

**NOTE C - SPLIT INTEREST AGREEMENTS**

The Cancer Research Foundation has been named the beneficiary of the following split interest agreements which have been recorded in accounts receivable and are considered temporarily restricted due to time restrictions:

	2000	1999
Donor A.....	\$ 50,671	\$ 50,671
Donor B.....	76,345	76,345
Donor C.....	605,605	605,605
	<u>\$ 732,621</u>	<u>\$ 683,005</u>

**NOTE D - INVESTMENTS**

Investments are stated at fair value as of March 31, 2000 and 1999. Cost of donated securities is determined at the fair value of the securities on the date of receipt. Investments consist of the following at March 31, 2000 and 1999:

	2000	1999
Money market fund .....	\$ 201,335	\$ 215,972
U.S. Government bonds .....	350,406	1,141,388
Corporate bonds and warrants .....	1,362,635	521,466
Stocks and securities .....	2,911,382	2,822,013
	<u>\$4,825,758</u>	<u>\$4,700,839</u>

**NOTE E - PERMANENTLY RESTRICTED NET ASSETS**

The Foundation received endowments totaling \$710,265 in fiscal 1989 and fiscal 1988 from the Eugene and Dorothy S. Fletcher Trust. The terms of the endowments require permanent investment of the principal, but permit the use of investment earnings for laboratory research.

**NOTE F - TAX STATUS**

The United States Treasury Department has advised that the Foundation is a not-for-profit corporation organized and operated exclusively for charitable and scientific purposes, is exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code, and is not a private foundation as defined in Section 509(a) of the Internal Revenue Code.

**NOTE G - LEASE AGREEMENT**

The Foundation is obligated for rental expense under a non-cancelable operating lease for office space. The agreement provides for annual base rents plus additional rents relating to future increases in the building's operating expenses and real estate taxes. At March 31, 2000 and 1999, future minimum rental commitments are as follows:

	Fiscal year ending	Amount
2001 .....		\$12,898
2002 .....		13,220
2003 .....		13,548
2004 .....		2,267
Total .....		<u>\$41,933</u>

During 2000, the Foundation incurred \$10,775 in rent expense.

**Connections...**  
continued from page 1

therapies that attack cancer cells.

The process of genetic fingerprinting however, requires sophisticated tools and equipment. To illustrate, one DNA sequencing machine alone costs over \$150,000. The human genome project used over 400 such machines running day and night. Similar expenses will be required to generate gene expression profiles for every human cancer type. Thus, the next generation of cancer research will rely on an incredible amount of resources and support from the public,

government, and the medical community.

The answer does not lie, however, solely in sophisticated equipment. It will rely on dedicated, intelligent, and curious scientists, like the Young Investigators that the CRF supported in 1999 and 2000: Wei Du, Ph.D., Carl Correll, Ph.D., Guido Franzoso, M.D., Ph.D., Lalitha Iyer, Ph.D., Michael Thirman, M.D., Suzanne D. Conzen, M.D., Bruce T. Lahn, Ph.D., Jonathan P. Staley, Ph.D., Joel Shilyansky, M.D., and Wouter Hoff, Ph.D. Whether these investigators use million dollar machines or the back of a scratch pad to make discoveries is not important. What is important is that they are committed to achieving the goal of

eradicating cancer in our lifetime and making cancer a thing of the past!

In conclusion, I believe that the focus of cancer research in the 21st century will be for investigators working in supportive environments such as the University of Chicago to identify the unique molecular characteristics of each type of cancer. Once the genetic and biochemical mechanisms that govern cancer development are better understood, a cure for cancer will not be far behind.

*(Special thanks to Melissa Karabinis, M.S., Research and Development Director of the UCCRC for assistance with this project.)*

**Special Occasion and Memorial Acknowledgement**

Gifts honoring the memory of someone dear who has died, or gifts in celebration of birthdays, anniversaries, a new home, a new baby or many other special occasions arrive at the Cancer Research Foundation daily.

This represents a current philanthropic trend in gift giving. Caring individuals and companies are making donations to CRF in someone's name, in lieu of client or staff gifts. It's truly a way to demonstrate that it is better to give than to receive.

Now it's even easier to give: In addition to personal checks and cash, you can charge your gift to VISA, MasterCard or American Express – by mail, by phoning our office, or online. Every contribution will receive a timely, personalized acknowledgement from CRE

For further information, contact the Cancer Research Foundation at (312) 630-0055 or dial our website [www.cancerresearchfdn.org](http://www.cancerresearchfdn.org).

**This Year You Can...**

**Give To The Cancer Research Foundation  
Through Payroll Deductions:**

- Combined Federal Campaign (CFC)
- State Of Illinois Campaign
- Cook County Campaign
- City Of Chicago Campaign
- Campaigns Managed By United Way
- Corporate Campaigns

**The Cancer Research Foundation Is  
Listed In The Alphabetical Index With A  
Code Number**

**If We Are Not Listed, You Can Write  
Cancer Research Foundation  
In The "Donor Option" Section**

**Bequests: Fiscal Year 1999-2000**

Pearl Caslow	\$ 1,000
<b>Chicago, Illinois</b>	
Sigmund Kacz Trust	42,900
<b>Chicago, Illinois</b>	
Helen G. Prempas	10,901
<b>Chicago, Illinois</b>	
June P. Zerbs	8,098
<b>Chicago, Illinois</b>	

The Cancer Research Foundation received bequests from the following individuals during fiscal year 1998-1999. Their generosity will provide much-needed funding for important cancer research projects in Chicago.

Like these caring people, you have the power to provide for future cancer research in your will. When you consult your attorney, the following is submitted as language which may be used:

*I give and bequeath to the Cancer Research Foundation, a not-for-profit corporation located in Chicago, Illinois*

a) specific bequest: *the sum of \_\_\_\_\_ dollars (\$ \_\_\_\_\_) for uses and purposes of said corporation.*

or

b) remainder: *all the rest, residue and remainder of my estate, for uses and purposes of said corporation.*

# Thank You... Thank You... To Our 2000 Donors

(April 1, 1999 - March 31, 2000)

**B**ecause of you, progress is being made. Your donations are used to fund the highest quality cancer research in Chicago. Every contribution is greatly valued and appreciated. THANK YOU FOR CARING!

Abbott Laboratories Employees Tricia and Bruce Abrams Janice Adkins Tom Adler Adducci, Dorf, Lehner, Mitchell & Blankenship, P.C. Roy and Vi Alberswerth Bob and Sis Albert Mona and Andy Albert Carey and Seena Allison Bell Ambrose American Legion Norwood Post No. 740 Barb Amos Jim and Karen Ander Arthur Andersen - ABA Division Mr. and Mrs. Paul G. Anderson Mollie Antler Francine and Joseph Anunciacion AON Consulting Applied Information Management, Inc. Dorothy Arbetman Bob and Janice Arcus Mrs. Florence Arendt Donna Armellino Lugene Armstrong Fausto Arneri Burt and Ella Arnov Artistic Dental Studio, Inc. Jeri and Ed Assadi-Otte Michael and Deborah Bade Wilford and Helen Bair Caroline and Bill Balmes Verna Bardsley Rose Baron Marilyn and Milt Barr Lindsay Barrix

Phyllis J. Bartoli Thomas B. and Gay C. Barton Rick and Ivy Baruch Irmgard Basaraba Dr. and Mrs. Alfred Bass Irv and JoAnn Bass Mitchell Bass Mary Fran Basso Hazel Bastin Richard Bauknecht Dolores Bauman Verna Beardsley Jeanne Beck Tom and Carole Beck Gerda Behrend Joe and Shirley Belmont Ethel K. Benedict Lena and Tod Benson Mr. and Mrs. Daniel M. Benzaquen Mr. and Mrs. John K. Bergeson Joan Berlow and Maurits VanderVeen Virginia Berndt and Randy Worthan Bertels Family Rae and Bud Besser Rose Bezouska Josephine Biegler Robert Biersach Mrs. David Bitensky Jean F. Bjorkqvist James Blaha Ruth Blanchard Ethel and Ralph Blinkwolt Mr. and Mrs. Sidney Bloom Janet and David Blum Board of Education, School District 64, Park Ridge Ken and Joyce Bohlin Linda Bollendorf William and Paz Bonin Deborah Bonner Mr. and Mrs. Eugene Boppart Debra and Jay Borodkin Peter and Heather Borzak Robert R. Bossert Ruth Boswell Mamie M.. Bowen Robert J. Boylan Marjory and Earl Brady Mr. and Mrs. Harry Brahmstadt Don and Grace Brandt Georgette Braun Suzy Braun Manuel and Marlene Bress Mitzie Bretzer Marla and Rand Brichta Myra J. Brundage Ernie and Kathy Brunke Herman and Sonny Bruski Mr. and Mrs. Herman Buchfuehrer and Family Florence Burkart Eva Burkhardt Helen M. Burkin Erika and Justin Burton Lorraine and Marv Burton Michelle Buzby Val Burke BWAY Winnetka Office Barbara and Bud Byers Mike, Robin & Joshua Byster Irene Camasta Archie and Evelyn Cameron Val Canavan Cantigny Post #367 Auxiliary Mr. and Mrs. L. Capchinske Anna Carin Valerie R. Carlin and Family Judith B. Carlsen James E. Carroll Mrs. Jennie J. Carsello JoAnn Caselli Josephine Cech Sophie Cerks Chamberlain Research Consultants, Inc. Henrietta S. Chasanov Evelyn Cheslow Chicagoland Bowling Proprietors Association Myrtle Christensen Dr. and Mrs. Anastase Christou Marilyn Chulock Flo and Sam Cianelli City of Country Club Hills Gail Clarke Classroom Teachers Association, School District 149, Dolton Sarah and Ken Clifford Brian J. Clucas Barbara and Marty Cohen Julian and Sharon Cohen Seymour A. Cohen Family Foundation Barbara and Carl Cohn Judy and Jerry Colbert Lorin Coles Patricia Conway Robert S. Cooper Susan and David Coren and Family Thomas A. Corfman and Carol A. Brook Helen Stella Costas Leslie Cotton Marie Coulson Harriet and Philip Cowan Creative Beginnings Don and June Croson Jane Crouse Elaine Culch Gertrude S. Cummiskey Dave and Cile Cunningham Czerwinski Family Mr. and Mrs. Paul Dahlquist Don Dame Judy Dan Sandra Danforth Dorothy J. Daniels Dori D'Anna Mr. and Mrs. Thomas D'Aprile Cele Davis Dolores Davis and Barbara Coxe Mr. and Mrs. Robert Davis Gail Deckert Lisa DeHorn Demi & Cooper Bunny and Johnny DeMuth and Family David and Margaret Denis Daniel and Miriam Derman Karen and Mike Devore Ray and Anna Lee Devorkin Londa DeWald Helene Dick Discover Financial Services, Inc., Training and Development Department Marge and Jack Dissen Judith Ditekowsky Mr. and Mrs. Sherwin Ditlove Bob and Mary Dixon Debra and David Dobkin and Family Mr. and Mrs. Philip Dobrofsky Eric and Char Doman Dominick's Pharmacy Staff in Niles Sandy Dony Sabina Dorio Bonnie and Howard Drazner Angela M. Druckrey Michael and Vicki Drumm Mr. and Mrs. Mel Drury Melvin E. Dryman Bernice and Stuart Dubin Bessie Dubsky Family Geri Jo Duda Steve Duffy Matthew and Lori Duggan Michael and Hedy Duggan Ronald Duitsman Richard and Alice Dukelow Fred and Marian Dumke Linda Y. Dunne Eastern Kentucky Social Civic Club Estelle Ecker Foundation Mary Eden Alice and Carl Edwards Mr. and Mrs. David Ehrenberg Joan Ehrhart James and Judith Ekola Yacoub and Emilia Elgamil Nancy Elliott Fred and Helen Ellis Charitable Foundation Merwin C. Ellis Lee Eng Alix Engel Charlene and Bruce Entman and Family Dr. and Mrs. Herbert M. Epstein Harry and Cathryn Eshbach Mrs. Michalina H. Ewers Lorraine and Murphy Fabian Margret E. Fairhead Joan and Vince Falaschetti Bonnie and Joe Falatek Thomas Fantasia Al Feig and Family Feltes Sand & Gravel Co. Anita and Chick Ferlito Edwin L. Ferguson Teddy Fershtman Fidelitone, Inc. Virginia S. Fijak John and Cathy Filippo Finish Line, Inc. William and Patricia Finlay Bruce and Barbara Finn First Options of Chicago, Inc. John and Donna Fischer Joyce Fishbain Dorothee Fisher Lois and Culver Floyd Sally N. Fohrman Terry and Donald Fohrman Mrs. Josephine Formato Fox River Valley Kennel Club, Inc. Mrs. Theodore Fox Marcia and Thomas Fraerman Dolores Zelko Frankovich Michael J. Freed Ruth and Gene Freedman Maury Frenz Mardy and Terry Fried Alan Friedlander James Friedlieb Irving and Abigail Friedman Pearl Friedman Robert Friedman Friedman Properties Daniel M. Friend Susan Fritz Michelle Frost and Kathy Quinn Jeanne M. Fuhrmann Nancy Furman Ed and Paula Gafron Gage Park Woman's Club Joyce and Don Gale Mr. and Mrs. Frank Garner Mr. and Mrs. George Gaskin Tom and Joann Gawczynski Peter C. Geannopoulos Florine and Paul Gelfman Employees at General Dynamics Steven G. Gersten Barbara S. Geshkewich Getz-Sheftel Family Floyd Gilbert Frances Gilbert Peter and Aimee Gilbert Thomas E. Giles Monica, Noah and Jordan Ginsburg Belle Glass Joel and Peggy Glickman Marcy Gloede Dr. and Mrs. Dusan Gokjovich Karen Goldberg Alexandra E. Goldblatt Nathaniel Goldblatt Stanford J. Goldblatt Mitch and Myrna Goldman Robyn R. Goldman Sid and Bev Goldman Joan R. Goldsmith Larry and Janice Goldstein Rodney L. Goldstein Mindy and Dan Golman Arlene and Archie Golub Maurie and Harriet Goodwin Gary Goolsby Les and Rick Gordon Norma and Lester Gordon Alan and Linda Gordoni Joan C. Gosenski Margaret Grabowski Michael Graff and Nancy Lerman Philip Graff and Janet Lerman-Graff Jeanne J. Graham Leslie and Corey Grauer and Family Jill Grayson Izzy and Bertha Green Rayna and Jerry Greenberg Greene Family Etta, Frank, Lisa and Craig Greenfield Mary Greiger Barbara Greis Jessie Griffin Family Sara Gross Dorothy Grzeskiewicz Charlotte M. Guidice Roz and Bill Gurtz Jean Guthrie Lily and Walter Gutmann Wendy Haidinyak Suzy Hakimian and Family Mr. and Mrs. Robert W. Hampton Jayne R. Hanauer Mrs. Donald R. Hardy Donald Harenberg Pete and Lois Harrell Harris Bank, Naperville Harris Bank, Residential Mortgage Division Laura Harris Mavis Harris Mary J. Hausman John and Maryann Hay Sharon Heald HealthNET Communications, Inc. Joe and Tina Heckel John and Marilyn Heise Beryl Heller Kathy Hennessy Pat and Dick Hereford Dorothy J. Hermann Edna Herrmann Sylvia and Alan Hertz Keith and Cindy Hesness Hey Machine Tools, Inc. Beatrice H. Heydeman Barbara L. Hill Lois H. Hill Mary Hill Wallace and Beverly Hilleshiem Maggie Himmel Robin L. Hochstrasser Patricia Hofbauer Michael and Susan Hoffman Eva Hofman Lucille Holle Helene Hollub Mary and Dave Holtzblatt Alicia Honan and Family Carol A. Hoover Mark Homung and Dan Godhardt and the Circulation Dept., Chicago Sun-Times John R. Howe Rosalie Howe Alice Howell Bradley and Rebecca Hull Brad and Kathy Hunt Mayme Hurlley Rick and Janet Hyken Thomas and Connie Hyland Illinois Lawn Equipment Intelligent Computer Solutions, Inc. Mr. and Mrs. Jim Isaacs Keith Ishaug and Sarah Lagimodiere Mary Israel Ikue Itami Bill Izzo Minnie Jablonski Louise M. Jarog Ida Jenkins Martin L. Jesser Mary Ann Jirga Dorothy B. Johnson Alice Jorgensen Mrs. Lucille Justinic Raymond F. Justinic Carol S. Kane Romas J. Kankus Elaine S. Kaplan Allan and Ronna Kaye Kaplan Lucille C. Karella Mr. and Mrs. Steven Kari and Family Dale Karolak and TRW Karen Kasperski Leo and Edie Katalinas Mr. and Mrs. Thomas J. Katsules Edith Katz Fran Katz Marilyn and James Kavanaugh Edward and Loretta Kay Kaye Productions Eva Kearns Keebler Company Jeanne and Carl Keeshin Wayne Kempf Peggy Kendall Jeanne Kelty Richard and Barbara Kennerley Dennis and Barb Kessler Stella and William Ketter Jeff Kiley Barbara Kilger Christine King Patrick R. King Bert F. Kinister, Jr. Theresa Kirby Marilyn and Neal Kirschenbaum Karen Kirschenbaum Mrs. Amelia Kiwak Linda Klawitter Dorothy K. Klich Louis and Fran Klus David and Caroline Knutson Richard Kochanski Josephine Koehler Michael J. Koetting Frances Kokos Tony and LuAnn Kolodzinski Angelo and JoAnne Kopetas Michael Kopetas Mrs. Pauline Koransky Lillian T. Korilko Lee Kovarsky Richard Kowalski Family K Plus Incentives, LLC Anne Kramer Ilene Kramer Martie and Jerry Krassek Richard Kreutzfeldt Sandra L. Kruml Judith K. Kubert Betty and Ken Kula Andrew and Dana Kull Mr. and Mrs. Thomas R. Kully Virginia Kunze

# Thank You... (continued)

Georgiana G. Kysar Eileen Labak Helen Lachman Mike Lachman and Lillian Shamest Lake County Farm Bureau Tracy and Debbie Lancaster  
Bernie Landis Mr. and Mrs. Fred Lane Jan Ellen Lane Stephen W. LaPorte John and Mary LaPrairie Margaret LaRaia and Family Bob  
and Barbara Lasky Charlene N. Lavin Bob and Janet Lee and Family Becky and Dean Leff Nathan and Shirley Leff Loretta R. LeForge and  
Family Lillian Lekovich Louise Z. Lenz Sylvia Lerner Arlene and Jeff Levin and Family Carol and Craig Levin Elaine and Larry Levin  
Ross A. Levin Frieda Levine Alice and Harold Levy Eadie Levy Penny, Sarah and Ike Lichter Elise and Marc Liebow Flora Lindberg Jay  
and Joy Liss Lois and Marvin Liss Billee Berman Litvack Lodge Slavija No. 1 Ruth and Sidney Loeb Wayne and Mary Loftsgaarden Anna  
Marie Logan Jane and Steve Lorch Kathleen Lotz Ludwig Explosives, Inc. Elliott and Norma Lundberg Karen Lundin Virginia Lundstrom  
Cindy Loren Lupatkin Bob and Joan Lurie Elaine and Nicholas Lyttek and Family Lisa A. MacGillivray Edna Macquilkin Madame  
Alexander Doll Club Beatrice Magee Marion Magon and Family Anthony P. Mahowald Maine South High School Students Geraldine and  
Honore Malicki Marion and Nelda Maner Grace E. Mark Arlyne M. Marks Muriel Marks Nancy Marszalek Sandy March Mrs. Ann  
Martin Bob and Anne Masheris and Family Michael D. Mason Mr. and Mrs. I. T. Matuszewski Margarita Matzick Marie Maxwell Robert  
and Helen Mayfield Mel and Millie Mayster Glenn Mazzuca and Son Mr. and Mrs. Victor R. Mazzucco Edward J. McAdams Zella and Ida  
McClure Mrs. Jeanine M. McGorin Rose McKane Charlotte McQuillan Medinah Middle School District No. 11, Roselle Karen and Kenneth  
Megaw Judy and Elmer Melnick JoAnne Melton Zelma Meltzer Evelyn Melum Howard and Barrie Menaker Mary and Jim Mergenthaler  
and Family Bill and Clare Mertz Carol M. Mertz May E. Mesco David Metzner, B & G Sales, Inc. Ann and Alan Meyers Howard and Anne  
Michael Joanne Michalski Rudy and Sue Mihelich John Millen Dixie Miller Doris J. Miller Mr. and Mrs. Eldon Miller Erika and Girard  
Miller James V. Miller, Jr. Jim and Debbie Miller Deborah Millner Milosavljevic Family Mist Chemical and Supply Company Naomi L.  
Moderick Gail and Tony Modro Karen Moore Thomas M. Moriarty and Marta Wozniak Martha Moris Justin R. Morozewicz Cathy and  
V.C. Morris Karen Mowinski Marty and JoAnn Nardiello Lil and Alf Nathan Vivian Neary Nancy and Todd Needlman Anna M. Nelli  
Helen and Harry Nelson Jean Nelson Joel and Sherri Nemirow Earl and Harriet Newman Fran Nichol Allen Nichols Rose Niedzwiecki  
Mr. and Mrs. Jeffrey Niemiec Mr. and Mrs. Leo Niemiec Adil Nizamuddin Marie Nordenberg Susan North Carol Northcutt Northwest  
Herald Bernice Notarius Carol M. Novak Jan Novak Bernie and Dolores Nyquist Beth and Pat O'Driscoll Marjorie Oftedahl Gwen B.  
O'Loughlin David and Gail Olsen Marion and Janet Olson Scott and Robyn Olson Catherine O'Rourke and Family Gail Ostrum Ian S.  
Oxman David Pacini Sandra K. Palmer Dan and Margaret Papie John Parent Geraldine Parrilli Eugina Parsons Brian and Karen  
Patterson Barry Paul William and Sybil Paullin Thomas Payden Family Blanche Payne and Annie Mary Spencer Kathi Peacock Mr. and  
Mrs. Steven Pearl Sonny and Marsha Pearlstein Les and Bea Peilet Lolita Peotter Kristine L. Perry Mr. and Mrs. Robert Peterson Peter J.  
Petrakos Evelyn J. Petrie Michael and Mary Jo Pfammatter Hope Pinckney Juliana and Phillip Pinzetti Emil A. Pisola Catherine Pistorosi  
Mrs. Mildred Pitt Pat Plate Joan and Preston Plusser Phyllis Pollock Carol Pomerantz Pomponi Family Kimberley Pope Jason Popp  
Robert and Cecelia Popp Mr. and Mrs. Steve V. Porrello Esther Port Irving and William Port Dorothy M. Pote Suzanne and Jay Powell PPG  
Industries, Inc. Premier International Jane R. Prentis Bernie and Arlette Pritzker Patricia Prokopp Michael J. Pusateri Priscilla H.  
Quackenbush Scott Quackenbush and Family Quarry Consumables & Equipment Company, Inc. Patricia Rackouski LeRoy Radtke, Sr. Bette  
and Herb Raef Mr. and Mrs. Dominic Ramundo Raymond's Hair Design RCG Information Technology Employees Agnes E. Reder Jackie  
Reuland Sharon Reeves Lorraine M. Rehling Theodore H. Reimer Marilyn and Edward Rein Elsie Reining Betty and Jack Reuben Milt  
and Ronnie Rich Arline Richter Eleanor C. Rickter Mr. and Mrs. Angelo Riforgiate Sherilyn Ritter Mary Roberti and Family Ann and  
Mickey Roberts Joseph and Gloria Robertson Esther Robinson Pat and Irene Roche Marshall and Betty Rodin Harold Roeth Frank and  
Robyn Rogers Joelyne M. Rogers Ann Rogul Juliette C. Romeo Philip and Myn Rootberg Foundation Paul and Margaret Rose Sue Ann  
Rosen Dr. and Mrs. William Rosenberg Mary E. S. Rosenthal Herb Roskin Prestige Pharmacy Marsha Rosner Gertrude T. Ross Renee and  
Ed Ross Anthony F. Rossi Fran and Lou Roston Fred and Betty Roth Melinda Roussos Elaine and Ben Rozansky Dennis and Marlene  
Ruber and Family Teri and Roger Rudich Paul W. Runkel Tina and Buzz Rutenberg Mr. and Mrs. James Ryan David and JoAnn Sachs Lil  
and George Saewert Michael, Sandi, Phil and Dan Saken Laurence and Renee Salasche and Family Emil L. Salay Carol A. Salm Marlene and  
Bruce Saltzberg and Family Rudy Sanchez Doctors Sanders, Lio, Chemick, Proctor and Staff Bob Satterfield Carolyn Sawdey Dorothy and  
Morris Saxner Kathy Scaccia Sam and Frances Scalafini Sheldon and Cookie Schaffel Lisa Schenkman Schiller Family Christine Schmid  
Eugene Schmittgens Elaine Schneider Janszen and Bre Schneider Robert and Linda Schmorbus Dolores L. Schon Edna L. Schrank Ann M.  
Schultz Mr. and Mrs. Carl Schultz Alma Schumann Yolanda Sue Schutz Edward and Trudy Schwartz Jody Schwartz Reva and Mickey  
Schwartz Richard and Jeanne Schwartz Mrs. John Schweis Carole and James Sciarine Ceil Scuito Mr. and Mrs. Donald Seadle Richard  
Segert Mrs. Yolanda Seghetti Blossom Seigel Jacklyn Serafin Frank and Dolores Seymour SG Supply Company, Norman and Craig Weiss  
Dorothy Shainberg Mr. and Mrs. Ray Shank Sol and Lena Shapiro John Sharkey Richard and LaVerne Sharkey Kathryn Sheldahl Alice and  
Seymour Shelist Charlotte and Joe Shery Diane and Leonard Sherman Thomas C. Shields Norma Shockey David L. Shores Annamae Sica  
Marilyn Sidran Anne Silverman Gussie Silverman Frank and Elizabeth Siracusa Tony and Mary Sirtaut Lyle Sitterly, Jr. Gen Siwinski and  
Rich Omiecinski Dolores Sloan Christine Smith Irene Smith Judy and Stuart Smith Shirley J. Smith Theresa M. Smith Shirley Smolin and  
Karpis Ed and Marge Smolinski Sidney and Jean Solomon Josephine and Martin Spanich Sheila and Harris Spanier Betty Speers Mabel  
Spencer Stella Splavec St. Paul Companies, Inc., Foundation Walter Stadler Mr. and Mrs. Theodore J. Stanek, Jr. Ellen and Charles Stannard  
Joni Starmer and Family Mr. and Mrs. Norbert Stawicki Cathy and Byron Stein Frances Steinmeier Irving Stenn, Jr. Audrey and Bob Stern and  
Family Dr. and Mrs. Paul Sternberg Edie and Paul Sternfeld Bruce and Patricia Stiles Debby and Dale Strauss Mr. and Mrs. Daniel Streicker  
Irene J. Strohl Rosalyn Strom Ruth Strzechowski Bernice Suarez Carol A. Suerth Jeanne K. Susman Robert M. Swanson Sharon and Lloyd  
Swanson Shirlee Swetin Seena Swibel Mary Ann Taft Bobbi and Jim Taormina Cindy Tassio Mr. and Mrs. Bruce Taylor Elsa E. Taylor  
Linda L. Taylor Iris and Sid Taylor Telephone Pioneers of America, Indian Trails Life Member Club Tempographics, Inc. Deborah Thar Helen  
Thien Pamela J. Thomas Eldon and Brandy Thompson Sandy and Bill Thompson Keith Thurnell Susi and Dan Todd Ann Todisco Judith  
A. Tondy Nancy Toon Roberta Topel Total Research Strategic Marketing Services, United Kingdom Tower Oil & Technology Co. Douglas and  
Leslie Tozier James E. Trausch Travel Technology Group Mrs. Erna Truskolaski and Son Fred and Brenda Turner Jan Tybon Beverly Ukleja  
Dr. and Mrs. Upton Urban Retail Properties Company Tom Usry Mary Catherine and Dick Valack Linda and George Van Geem Mary Jane  
Van Thyne Sharon Varga and Family John Z. Vasquez Family Julie Veit Gregory and Jeannie Verkan Jeannine Vivo Dorothy and Bob  
Vondran Joe and Loretta Votava David R. Waal Eleanor Waal George Waal, Jr. Dick and Lucille Wallis Mary K. Walsh Tom and Connie  
Warsaw Linda Washington Waterlink Separations, Inc. Shirley and Quinn Waterloo Myron and Nancy Weber Wednesday Lunch Bunch  
Charles B. F. Weeks Harold and Esther Weinberg Mr. and Mrs. Mark Weinstein Lorraine Weinzimmer Brent and Diane Weiss Jill Weiss Mr.  
and Mrs. Marvin Weiss Thomas A. Weiss Harriet and Harold Wendt Steve and Opal Werenksi Karen Werner Denise Wermes Renee Wexner  
Mrs. Beverly Wexstein Bernice and Seymour White Mrs. Eugene Wiecek Corey and Rowann Wieczorek Milt and Barab Wikell JoAnn Wilkin  
Alexis Richards Williams Alice Williams Alice Willis Wilmington Island Park District Marilyn Wilson Naomi and Bill Wilton Linda and  
Charles Wind and Family Don and Gerry Wing Wisconsin Bureau of Aging and Long Term Care  
Resources Judy and Harold Witkov Lisa M. Witkowski Bill and Joanne Wittig Leonard S. Wolf  
& Associates Mr. Richard Wolff Rosemary Wolff Mary Wombold Women of the Moose,  
Southwest Chicago Chapter 110 Christine Woolf Ron Workman Family M. Josephine Wozniak  
Scott, Bob and Mary Wolff Xerox Corporation John and Marianne Yates Bill and Bonnie Yeaman  
Joe and Wilma Yechout Travis Young Mary Yusk Tom and Janet Zarley James J. Zelko, M.D.  
Jeanette Ziemer Mr. and Mrs. S. R. Zilberstein Seymour Zimmerman Mr. and Mrs. Nat Zivin  
Barbara and Leon Zuckerman Mrs. Ruth Zuger and Margie Janet and John Zuidema Zurich  
American Insurance Company, Claims Management Michael and Stephanie Zvirin

Your name is not for sale. The Cancer Research Foundation does not buy, rent or sell donors' names. We believe that your gifts to fund cancer research are truly gifts from the heart, and we will not raise money by selling your right to privacy.



# CANCER RESEARCH FOUNDATION

Office: 135 S. LaSalle St., Suite 2020 • Correspondence: P.O. Box 0493, Chicago, IL 60690-0493  
312.630.0055 • Fax: 312.630.0075 • website: <http://www.cancerresearchfdn.org>

## Holiday Cards

We have nine full-color holiday cards – pictured here are five.

For a catalog and ordering instructions, call our office at (312) 630-0055 or e-mail us at [crf@cancerresearchfdn.org](mailto:crf@cancerresearchfdn.org)



Newsletter Design and Mail Fulfillment by Executive Services & MailHouse. Professional Photography by Vanek and Associates.

## Cancer Research Foundation

### BOARD OF TRUSTEES:

#### Chairman of the Board:

Mrs. Maurice Goldblatt  
Chicago

#### President:

Merle Goldblatt Cohen  
Chicago

#### Vice-President:

Mr. Stanford J. Goldblatt  
Attorney, Winston & Strawn  
Chicago

#### Secretary-Treasurer:

Mr. Edward J. McAdams  
President, McAdams Associates, Inc.  
Chicago

#### Trustees:

Mrs. Stanley D. Braun  
Community Volunteer  
Chicago

Mr. Michael J. Freed  
Attorney, Much Shelist Freed Denenberg  
Ament Bell & Rubenstein, P.C.  
Chicago

Mr. Rodney L. Goldstein  
Managing Partner, Frontenac Company  
Chicago

Mr. John J. Piva, Jr.  
Vice President, Duke University  
Durham, North Carolina

Mr. Thomas C. Shields  
Attorney, Bell, Boyd & Lloyd  
Chicago

#### Medical Consultant:

Joseph B. Kirsner, M.D., Ph.D.  
Louis Block Distinguished Service Professor  
University of Chicago Medical Center  
Chicago

#### Legal Counsel:

Mr. Clifford Harstad  
Attorney  
Chicago

#### STAFF:

Executive Director:  
Sharon Swanson

As a responsible member of the community, the Cancer Research Foundation believes in accountability. We think the more you know about our trustworthy stewardship of funds, the more willing you will be to invest in the future through the Cancer Research Foundation.

Every year, the Cancer Research Foundation files a report with the Internal Revenue Service, IRS Form 990 (Return of Organizations Exempt from Income Tax). This report is available for public inspection in our office. We also make it available by mail, at a nominal cost.

Cancer Research Foundation financial records are audited annually by Grant Thornton. Their report for fiscal year 1999-2000 is reprinted in its entirety in this newsletter.



The Cancer Research Foundation is an Illinois 501 (C) (3) not for profit corporation, operating in Chicago. Our mission is to help find the cures for cancer through research. We welcome memorial contributions and gifts in honor of special celebrations. Contributions are deductible to the full extent allowed by law.